Skip to main content

Hepatocellular Carcinoma News

Related terms: Malignant Hepatoma, HCC, Liver Cancer

Most Liver Cancers Are Preventable, Study Says

TUESDAY, July 29, 2025 — Liver cancer: In most cases, it doesn’t have to happen, a new global study finds. Research suggests that 60% of cases of this often deadly disease are preventable by avoiding ...

Most Liver Cancers Are Preventable, Study Says

TUESDAY, July 29, 2025 — Liver cancer: In most cases, it doesn’t have to happen, a new global study finds. Research suggests that 60% of cases of this often deadly disease are preventable by avoiding ...

FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer

TUESDAY, April 15, 2025 – The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic...

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

PRINCETON, N.J.--(BUSINESS WIRE) April 11, 2025 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (...

Statins May Reduce Risk for Hepatocellular Carcinoma in Chronic Liver Disease

WEDNESDAY, March 19, 2025 – For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study...

Dose-Dependent Link Seen for Alcohol, Cirrhosis, Liver Cancer in Patients With Hep B

WEDNESDAY, Jan. 29, 2025 – For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and hepatocellular carcinoma (HCC), according to a review...

TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer

THURSDAY, Jan. 16, 2025 – For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the addition of lenvatinib and pembrolizumab is...

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications

PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...

PIVKA-II-Based Model IDs Liver Cancer Risk in Hep C-Related Cirrhosis

THURSDAY, Dec. 5, 2024 – Among patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAAs), a serum protein induced by...

Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B

TUESDAY, Sept. 17, 2024 – A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB), according to a study...

Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer

TUESDAY, Sept. 10, 2024 – For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone,...

Women With Liver Cancer Less Likely Than Men to Receive Liver Transplant

MONDAY, Sept. 9, 2024 – Women with hepatocellular carcinoma (HCC) are less likely to receive a deceased-donor liver transplant (DDLT) and more likely to die while wait-listed than men, according to a...

FDA Approves Imjudo (tremelimumab) in Combination with Imfinzi for Patients with Unresectable Hepatocellular Carcinoma

24 October 2022 – AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular c...

FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma

South San Francisco, CA – May 29, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...

Lilly's Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma

INDIANAPOLIS, May 13, 2019 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

Keytruda, Opdivo